SciRev ratings (provided by authors) (based on 1 review)

Duration of manuscript handling phases Click to compare
Duration first review round 0.9 mnths compare →
Total handling time accepted manuscripts 0.9 mnths compare →
Decision time immediate rejection n/a compare →
Characteristics of peer review process Click to compare
Average number of review reports 1.0 compare →
Average number of review rounds 1.0 compare →
Quality of review reports 2.0 compare →
Difficulty of reviewer comments n/a compare →
Overall rating manuscript handling 2.0 (range 0-5) compare →

Latest review Show all reviews

First review round: 4.0 weeks. Overall rating: 2 (moderate). Outcome: Rejected.

Show all »

Journal info (provided by editor)

Issues per year
8
Articles published last year
139
Manuscripts received last year
220
% accepted last year
63
% immediately rejected last year
n/a
Open access status
optional
Manuscript handling fee?
yes
Fee per page
$105
Kind of complaint procedure
Other
Two-year impact factor
4.60
Five-year impact factor
4.80

Aims and Scope

mAbs is a multi-disciplinary journal dedicated to the art and science of antibody research and development. The journal has a strong scientific and medical focus, but also strives to serve a broader readership. The articles are thus of interest to scientists, clinical researchers, and physicians, as well as the wider mAb community, including our readers involved in technology transfer, legal issues, investment, strategic planning and the regulation of therapeutics.

mAbs publishes relevant and timely original research, as well as authoritative overviews, commentary and perspectives providing context for the work presented in mAbs and for key results published elsewhere. Original research papers may cover all topics important in the antibody field, including studies of targeted proteins t